Results for tag: "Von Willebrand Disease Drug"

Von Willebrand Disease (VWD) is a rare inherited bleeding disorder caused by a deficiency or defect in the von Willebrand factor (VWF). The von Willebrand Disease Drug market is a subset of the Hematological Drugs market, which includes drugs used to treat blood-related disorders. VWD drugs are used to treat the symptoms of VWD, such as excessive bleeding, and to prevent bleeding episodes. These drugs are typically administered intravenously or subcutaneously, and may include desmopressin, antifibrinolytics, and recombinant VWF. The Von Willebrand Disease Drug market is highly competitive, with several major players. These include Shire, Pfizer, Novo Nordisk, CSL Behring, and Bayer. Show Less Read more